PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
22.06%
Positive revenue growth while CRON.TO is negative. John Neff might see a notable competitive edge here.
127.38%
Gross profit growth at 50-75% of CRON.TO's 199.28%. Martin Whitman would question if cost structure or brand is lagging.
38.32%
EBIT growth similar to CRON.TO's 41.05%. Walter Schloss might infer both firms share similar operational efficiencies.
38.32%
Operating income growth at 50-75% of CRON.TO's 66.23%. Martin Whitman would doubt the firm’s ability to compete efficiently.
65.75%
Net income growth under 50% of CRON.TO's 423.76%. Michael Burry would suspect the firm is falling well behind a key competitor.
66.67%
EPS growth under 50% of CRON.TO's 404.59%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
66.67%
Diluted EPS growth under 50% of CRON.TO's 404.59%. Michael Burry would worry about an eroding competitive position or excessive dilution.
5.20%
Share change of 5.20% while CRON.TO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
5.20%
Diluted share change of 5.20% while CRON.TO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
293.60%
Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
184.22%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
-34.22%
Negative 5Y CAGR while CRON.TO stands at 275.38%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-9.09%
Negative 3Y CAGR while CRON.TO stands at 14.50%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
2504.48%
10Y OCF/share CAGR above 1.5x CRON.TO's 205.78%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
162.10%
5Y OCF/share CAGR 1.25-1.5x CRON.TO's 113.13%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
185.89%
3Y OCF/share CAGR above 1.5x CRON.TO's 120.94%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-113.65%
Negative 10Y net income/share CAGR while CRON.TO is at 200.15%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-168.21%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-153.14%
Negative 3Y CAGR while CRON.TO is 131.89%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
9548.01%
10Y equity/share CAGR above 1.5x CRON.TO's 1307.23%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-27.53%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-56.57%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.57%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
3.26%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
2.91%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-2.10%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-19.58%
We’re deleveraging while CRON.TO stands at 8.96%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
271.70%
We increase R&D while CRON.TO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
36.61%
SG&A growth well above CRON.TO's 0.63%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.